	US 12,447,202 B2
	Arthrospira platensis oral vaccine delivery platform
James Roberts, Seattle, WA (US); Michael A. Tasch, Seattle, WA (US); and Tracy Saveria, Seattle, WA (US)
Assigned to Lumen Bioscience, Inc., Seattle, WA (US)
Appl. No. 17/056,306
Filed by LUMEN BIOSCIENCE, INC., Seattle, WA (US)
PCT Filed May 17, 2019, PCT No. PCT/US2019/032998 § 371(c)(1), (2) Date Nov. 17, 2020, PCT Pub. No. WO2019/222711, PCT Pub. Date Nov. 21, 2019.
Claims priority of provisional application 62/672,891, filed on May 17, 2018.
Prior Publication US 2021/0213124 A1, Jul. 15, 2021
Int. Cl. A61K 39/015 (2006.01); A61K 39/00 (2006.01); A61P 37/04 (2006.01)

CPC A61K 39/015 (2013.01) [A61K 39/00 (2013.01); A61P 37/04 (2018.01); A61K 2039/51 (2013.01); A61K 2039/542 (2013.01); A61K 2039/545 (2013.01); C12N 2730/10034 (2013.01); C12N 2750/14334 (2013.01)]

12 Claims

1. An oral antigenic composition comprising:

a recombinant Spirulina, wherein the recombinant Spirulina comprises an exogenous nucleic acid sequence, encoding:

a chimeric protein comprising an antigenic epitope translationally fused to a viral protein or a virus-like particle (VLP)-forming protein wherein the exogenous nucleic acid sequence is stably integrated into an endogenous locus of the Spirulina; and

one or more pharmaceutically acceptable excipients.